Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer
Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-fr ee survival (PFS) for the initial (first-line) treatment of people with metastatic triple-negative breast cancer (TNBC), in the PD-L1-positive population. The data for the secondary endpoint of overall survival (OS) showed a negative trend, however, the study was not powered for the secondary endpoint of O...
Source: Roche Media News - August 6, 2020 Category: Pharmaceuticals Source Type: news
Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer
Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-fr ee survival (PFS) for the initial (first-line) treatment of people with metastatic triple-negative breast cancer (TNBC), in the PD-L1-positive population. The data for the secondary endpoint of overall survival (OS) showed a negative trend, however, the study was not powered for the secondary endpoint of O...
Source: Roche Investor Update - August 6, 2020 Category: Pharmaceuticals Source Type: news
SVR From DAA, Interferon-based Treatments for HCV and HCC Risk SVR From DAA, Interferon-based Treatments for HCV and HCC Risk
How does sustained virologic response from direct-acting antiviral and interferon-based treatments impact the risk of developing hepatocellular carcinoma?Journal of Viral Hepatitis (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - August 5, 2020 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news
Pembrolizumab too costly as 2nd-line therapy of hepatocellular carcinoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 31, 2020 Category: Drugs & Pharmacology Source Type: news
HCC in Chronic HCV Patients Who Achieved SVR HCC in Chronic HCV Patients Who Achieved SVR
Does achieving SVR with DAAs reduce the incidence of hepatocellular carcinoma in chronic hepatitis C patients, genotype IV with liver cirrhosis and advanced hepatic fibrosis?Journal of Viral Hepatitis (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - July 17, 2020 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news
Sequential Systemic Treatment in Patients With HCC Sequential Systemic Treatment in Patients With HCC
This study investigated the feasibility and efficacy of sequential systemic treatments with currently available and recently approved drugs for the treatment of hepatocellular carcinoma.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 13, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers and is difficul...
Source: Roche Investor Update - July 13, 2020 Category: Pharmaceuticals Source Type: news
Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers and is difficul...
Source: Roche Media News - July 13, 2020 Category: Pharmaceuticals Source Type: news
Viral Exposure Signature Predicts Hepatocellular Carcinoma
Signature can identify hepatocellular carcinoma patients before clinical diagnosis (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 10, 2020 Category: Cancer & Oncology Tags: Gastroenterology, Infections, Oncology, Pathology, Journal, Source Type: news
Viral Exposure Signature Predicts Hepatocellular Carcinoma
FRIDAY, July 10, 2020 -- A viral exposure signature can predict hepatocellular carcinoma (HCC) risk before clinical diagnosis among at-risk patients, according to a study published online June 10 in Cell.
Jinping Liu, Ph.D., of the National Cancer... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 10, 2020 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer
Basel, 18 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion031 study, evaluating Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel; followed by doxorubicin and cyclophosphamide) in comparison to placebo plus chem otherapy (including Abraxane), met its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in pathological complete response (pCR) for the treatment of people with early triple-negative breast cancer (TNBC), regardless of PD-L1 expression.“Triple-negative bre...
Source: Roche Media News - June 18, 2020 Category: Pharmaceuticals Source Type: news
New Blood Test May Improve Liver Cancer Screening
The test checks people for previous exposure to certain viruses that may interact with the immune system and increase the risk of hepatocellular carcinoma (HCC), according to their new study. (Source: WebMD Health)
Source: WebMD Health - June 17, 2020 Category: Consumer Health News Source Type: news
Deep learning detects HCC on contrast-enhanced MRI
A deep-learning algorithm can detect hepatocellular carcinoma (HCC) on contrast-enhanced...Read more on AuntMinnie.comRelated Reading:
Functional, diffusion MRI could benefit from AI
MRI identifies biomarkers for aggressive HCC subtype
CE-MRI with CT extends life for patients with liver cancer
AI tops recent imaging informatics highlights
Beyond the black box? AI algorithm explains decisions (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 12, 2020 Category: Radiology Source Type: news
Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective
Paper proposes treatment recommendations related to COVID-19 for the different stages of hepatocellular carcinoma (i.e. 0, A, B,& C), specifically in relation to surgery, locoregional therapies, and systemic therapy. It also suggests strategies to modify risk during pandemic. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 12, 2020 Category: Consumer Health News Source Type: news
NIH scientists develop blood test to help improve liver cancer screening
Test can help identify people likely to develop hepatocellular carcinoma, the most common form of liver cancer (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - June 11, 2020 Category: American Health Source Type: news
